L. Michael Glodé

Dr. Glode is a Professor Emeritus at the University of Colorado Cancer center. He has been a key clinical investigator in a number of urologic oncology trials and was co-PI on the Phase I, II, and III studies that led to the FDA approval of Lupron™. He continues to serve as a scientific advisor to a number of pharmaceutical companies in the urologic oncology space, including Janssen, Exelixis, among others. He is a co-editor for Oncology and reviewer for numerous oncology journals. Relevant publications to this project include:

Hussain, Maha HA, ...Glode, LM...et al. "Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu–positive urothelial carcinoma: ..." Journal of Clinical Oncology 25.16 (2007): 2218-2224

*Yang, Xiaoping,...Glode, LM... et al. "Diphtheria toxin–epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer." Clinical Cancer Research 19.1 (2013): 148-157.